Published in Antimicrob Agents Chemother on January 01, 2006
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother (2006) 3.25
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother (2008) 2.70
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis (2009) 2.33
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother (2007) 1.85
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis (2010) 1.60
How I treat mucormycosis. Blood (2011) 1.51
Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep (2010) 1.31
Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J Clin Microbiol (2006) 1.29
Management of neonatal candidiasis. Neonatal Candidiasis Study Group. Pediatr Infect Dis J (1998) 1.19
Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother (2008) 1.18
Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother (2008) 1.15
Zygomycosis in Immunocompromised non-Haematological Patients. Mediterr J Hematol Infect Dis (2011) 1.13
Mold infections of the central nervous system. N Engl J Med (2014) 1.11
Mucormycosis in immunochallenged patients. J Emerg Trauma Shock (2008) 1.10
Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. J Clin Microbiol (2011) 1.05
"We are what we eat!" Invasive intestinal mucormycosis: A case report and review of the literature. Med Mycol Case Rep (2012) 1.05
Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole. J Clin Microbiol (2009) 1.04
Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother (2011) 1.04
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. Antimicrob Agents Chemother (2009) 1.00
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother (2009) 1.00
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother (2006) 0.98
Rhizomucor variabilis var. regularior and Hormographiella aspergillata infections in a leukemic bone marrow transplant recipient with refractory neutropenia. J Clin Microbiol (2009) 0.97
Carbon assimilation profiles as a tool for identification of zygomycetes. J Clin Microbiol (2007) 0.92
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. Antimicrob Agents Chemother (2010) 0.90
Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis (2013) 0.87
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother (2010) 0.87
Posaconazole treatment for Apophysomyces elegans rhino-orbital zygomycosis following trauma for a male with well-controlled diabetes. J Clin Microbiol (2007) 0.87
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections. Clin Pharmacol (2015) 0.86
Drug Strategies Targeting CYP51 in Neglected Tropical Diseases. Chem Rev (2014) 0.86
Invasive fungal infections in acute leukemia. Ther Adv Hematol (2011) 0.86
Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections. Can J Infect Dis Med Microbiol (2008) 0.85
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. Antimicrob Agents Chemother (2007) 0.83
Combat-Related Invasive Fungal Wound Infections. Curr Fungal Infect Rep (2014) 0.83
Human fungal pathogens of mucorales and entomophthorales. Cold Spring Harb Perspect Med (2014) 0.82
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. Antimicrob Agents Chemother (2008) 0.81
Absidia Corymbifera in an immune competent accident victim with multiple abdominal injuries: case report. BMC Infect Dis (2007) 0.81
Mucormycosis in a renal transplant recipient: case report and comprehensive review of literature. Int J Nephrol (2014) 0.81
Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayl Univ Med Cent) (2007) 0.80
Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae. Antimicrob Agents Chemother (2006) 0.80
Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice. Antimicrob Agents Chemother (2009) 0.79
Mucormycosis, pseudallescheriasis, and other uncommon mold infections. Proc Am Thorac Soc (2010) 0.79
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. Antimicrob Agents Chemother (2010) 0.79
Invasive mold infections in solid organ transplant recipients. Scientifica (Cairo) (2014) 0.79
Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug Metab (2013) 0.79
Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag (2016) 0.78
Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother (2013) 0.78
Posaconazole in the management of refractory invasive fungal infections. Ther Clin Risk Manag (2008) 0.78
Therapeutic Drug Monitoring of Posaconazole: an Update. Curr Fungal Infect Rep (2016) 0.76
A review of clinical experience with newer antifungals in children. J Pediatr Pharmacol Ther (2008) 0.76
Pearls & Oy-sters: isolated cerebral zygomycosis in an intravenous drug user. Neurology (2011) 0.75
Rhino-orbital Mucormycosis: Clinical Findings and Treatment Outcomes of Four Cases. Turk J Ophthalmol (2015) 0.75
Management of rhinomaxillary mucormycosis with Posaconazole in immunocompetent patients. J Oral Biol Craniofac Res (2016) 0.75
Orbital complications of fungal pan-sinusitis in uncontrolled diabetes. Maedica (Buchar) (2013) 0.75
Posaconazole treatment in Korea: single-center experience over 5 years. Yonsei Med J (2013) 0.75
How should we manage a patient with invasive mucoromycosis who develops life-threatening reaction to amphotericin B? Report of two cases and literature review. Med Mycol Case Rep (2015) 0.75
Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient. Med Mycol Case Rep (2017) 0.75
Etest cannot be recommended for in vitro susceptibility testing of mucorales. Antimicrob Agents Chemother (2015) 0.75
[Invasive mycoses and trauma]. Wien Med Wochenschr (2007) 0.75
Pulmonary mucormycosis: clinical features and outcomes. Infection (2017) 0.75
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Zygomycetes in human disease. Clin Microbiol Rev (2000) 9.80
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2002) 6.99
Infections in patients with diabetes mellitus. N Engl J Med (1999) 5.39
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother (2002) 3.74
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect (2004) 3.26
Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis (2004) 3.20
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis (1998) 3.09
In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother (2002) 2.89
In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother (2003) 2.80
Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis (2000) 2.78
Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect (2001) 2.47
Voriconazole. Clin Ther (2003) 2.39
Pulmonary mucormycosis: the last 30 years. Arch Intern Med (1999) 2.38
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 2.31
Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med (2004) 2.30
In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother (2002) 2.15
Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother (2003) 2.09
Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis (2003) 1.86
Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica (2000) 1.77
Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol (1997) 1.77
Zygomycosis. Infect Dis Clin North Am (2002) 1.58
Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant (1999) 1.55
Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis (2001) 1.39
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother (2004) 1.33
Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect (2005) 1.32
Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med (2001) 1.21
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther (2003) 1.19
Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis. Mycoses (2004) 1.10
Cluster of pulmonary infections caused by Cunninghamella bertholletiae in immunocompromised patients. Clin Infect Dis (2000) 1.09
Disseminated zygomycosis due to Rhizopus schipperae after heatstroke. J Clin Microbiol (1999) 1.01
Fatal rhino-orbito-cerebral mucormycosis in an apparently normal host: case report and literature review. J Clin Neurosci (2001) 0.95
Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant (2004) 0.94
Eradication of invasive mucormycosis--effectiveness of the Echinocandin FK463. Hematology (2003) 0.92
Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. Eur J Clin Microbiol Infect Dis (2002) 0.91
Abdominal wall mucormycosis successfully treated with amphotericin and itraconazole. J Infect (2002) 0.90
Rhinocerebral mucormycosis in patients with burns: case report and review of the literature. J Burn Care Rehabil (1999) 0.88
Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. Clin Infect Dis (2001) 0.87
Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole. Braz J Med Biol Res (2002) 0.86
Successful non-surgical treatment of disseminated polymicrobial fungal infection in a patient with pancytopenia and graft-versus-host disease. J Infect (2000) 0.82
Successful treatment of rhinocerebral zygomycosis: a combined-strategy approach. Clin Infect Dis (1999) 0.81
Ensembl 2009. Nucleic Acids Res (2008) 25.38
Ensembl 2008. Nucleic Acids Res (2007) 20.67
Ensembl 2007. Nucleic Acids Res (2006) 20.10
Ensembl 2005. Nucleic Acids Res (2005) 15.13
Ensembl 2006. Nucleic Acids Res (2006) 11.66
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med (1999) 9.84
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev (1998) 9.76
A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med (1990) 7.92
The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis (1997) 7.09
Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science (1997) 6.75
Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA (1998) 6.49
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med (1999) 5.82
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Climate-driven ecosystem succession in the Sahara: the past 6000 years. Science (2008) 4.53
The Source and Prevention of Septic Infection of Wounds. Can Med Assoc J (1941) 4.41
Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet (2001) 4.12
Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother (2001) 3.87
The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol (2000) 3.86
The Mechanism of Cross Infection of Wounds in Hospital by Haemolytic Streptococci. Can Med Assoc J (1941) 3.54
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant (2010) 3.46
Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob Agents Chemother (1996) 3.44
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother (2001) 3.33
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother (2006) 3.25
Source and Transmission of Nasopharyngeal Infections. Br Med J (1946) 3.00
Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J (2002) 2.96
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82
Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis (1998) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant (2007) 2.74
Candida tropicalis: a major pathogen in immunocompromised patients. Ann Intern Med (1979) 2.71
Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis (1998) 2.61
Ovarian volume related to age. Gynecol Oncol (2000) 2.61
Use of a colorimetric system for yeast susceptibility testing. J Clin Microbiol (1995) 2.54
Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol (1997) 2.49
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol (1998) 2.48
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
New light on the history of penicillin. Med Hist (1982) 2.44
Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother (1997) 2.43
Can 40 seconds of compassion reduce patient anxiety? J Clin Oncol (1999) 2.33
Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med (1992) 2.31
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother (2006) 2.31
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol (2005) 2.29
Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol (1996) 2.28
Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis (1999) 2.28
Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion (1993) 2.22
MEASUREMENT OF GLOMERULAR FILTRATION RATE IN PREMATURE INFANTS. J Clin Invest (1948) 2.13
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis (1980) 2.10
THE SEROLOGICAL DIFFERENTIATION OF PATHOGENIC AND NON-PATHOGENIC STRAINS OF HEMOLYTIC STREPTOCOCCI FROM PARTURIENT WOMEN. J Exp Med (1935) 2.09
Grades as predictors of physicians' career performance: an evaluative literature review. J Med Educ (1973) 2.04
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Antagonism between C/EBPbeta and FOG in eosinophil lineage commitment of multipotent hematopoietic progenitors. Genes Dev (2000) 2.02
Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med (2000) 1.95
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol (1991) 1.94
Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis (2010) 1.88
Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke (2000) 1.85
Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol (1998) 1.84
An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect (1998) 1.82
Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology (1999) 1.80
A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol (1993) 1.76
The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol Oncol (1998) 1.76
Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infect Immun (2001) 1.75
Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother (2008) 1.71
Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia (2002) 1.71
Role of adenosine in the heart and circulation. Cardiovasc Res (1996) 1.64
Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (2000) 1.64
Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res (1994) 1.62
Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans. J Clin Microbiol (1996) 1.61
Neural substrates of facial emotion processing using fMRI. Brain Res Cogn Brain Res (2001) 1.61
A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol (1997) 1.59
Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis (2001) 1.57
Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis (2001) 1.57
Stroke and intracranial venous thrombosis during pregnancy and puerperium. Neurology (1998) 1.56
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood (1997) 1.54
Continuing participation supports ultrasound screening for ovarian cancer. Ultrasound Obstet Gynecol (2000) 1.53
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Adverse effects of maternal enterovirus infection on the fetus and placenta. J Infect Dis (1997) 1.47
The Gsh2 homeodomain gene controls multiple aspects of telencephalic development. Development (2000) 1.46
Does patient controlled analgesia delay the diagnosis of compartment syndrome following intramedullary nailing of the tibia? Injury (2004) 1.45
Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant (2009) 1.44
Infusion therapy team and dressing changes of central venous catheters. Infect Control Hosp Epidemiol (1999) 1.42
Spinal cord compression: the hospice perspective. J Palliat Care (1993) 1.42
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect (2012) 1.41
Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant (1996) 1.41
The fractional Talbot effect in differential x-ray phase-contrast imaging for extended and polychromatic x-ray sources. J Microsc (2008) 1.41
Massachusetts Weapon-Related Injury Surveillance System. Am J Prev Med (1998) 1.40
Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol (2008) 1.39
Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging (1991) 1.37
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia (2012) 1.37
Characterization and transcriptional regulation of the 2'-N-acetyltransferase gene from Providencia stuartii. J Bacteriol (1993) 1.36
Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol (2000) 1.36
Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis. Clin Microbiol Infect (2006) 1.36
Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol (1997) 1.35